	US 11,999,770 B2
	Peptides and nanoparticle formulations thereof
Mohamed El-Tanani, Bradford (GB); Paul McCarron, Londonderry (IE); and Ahmed Faheem, Sunderland (GB)
Assigned to UNIVERSITY OF BRADFORD, Bradford (GB)
Filed by University of Bradford, Bradford (GB)
Filed on Dec. 28, 2020, as Appl. No. 17/134,977.
Application 17/134,977 is a division of application No. 16/096,947, abandoned, previously published as PCT/GB2017/051222, filed on May 2, 2017.
Claims priority of application No. 1607593 (GB), filed on Apr. 29, 2016.
Prior Publication US 2021/0188929 A1, Jun. 24, 2021
Int. Cl. C07K 14/47 (2006.01); A61K 9/51 (2006.01); A61P 35/00 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/4703 (2013.01) [A61K 9/51 (2013.01); A61K 9/5153 (2013.01); A61P 35/00 (2018.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/4722 (2013.01); A61K 9/5146 (2013.01); A61K 38/00 (2013.01); G01N 2500/02 (2013.01)]

16 Claims

1. A method for inhibiting the binding of regulator chromosome condensation 1 (RCC1) to GDP bound Ras-related nuclear proteins (RanGDP) in a subject in need thereof, wherein one or more cells of the subject overexpress Ras-related nuclear protein (RAN), comprising administering to the subject a therapeutically effective amount of a peptide comprising the amino acid sequence of SEQ ID NO:5 to inhibit the binding of RCC1 to RanGDP in the one or more cells overexpressing RAN.